UAE Lymphoma Therapeutics Market Report 2023 to 2030

UAE Lymphoma Therapeutics Market Analysis

$ 3999

UAE Lymphoma Therapeutics Market was valued at $126.21 Mn in 2023 and is predicted to grow at a CAGR of 11.30 % from 2023 to 2030, to $267.03 Mn by 2030. The key drivers of this industry include escalating lymphoma incidence rate, increasing healthcare expenditure, and growing geriatric population. The industry is primarily dominated by Bristol Myers Squibb Company, F. Hoffmann-La Roche, Novartis AG, Kyowa Kirin, and Merck & Co. among others.

ID: IN10AEPH356 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Sarita Yadav

Buy Now

UAE Lymphoma Therapeutic Market Executive Summary

UAE Lymphoma Therapeutics Market was valued at $126.21 Mn in 2023 and is predicted to grow at a CAGR of 11.30 % from 2023 to 2030, to $267.03 Mn by 2030.

Lymphoma is a cancer of the lymphatic system, categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). HL is characterized by Reed-Sternberg cells, while NHL comprises various subtypes originating from lymphocytes. Symptoms include swollen lymph nodes, fever, weight loss, fatigue, and itchiness. Treatment options include chemotherapy, radiation therapy, immunotherapy, targeted therapy, and stem cell transplant, tailored based on the type, stage, and individual health status. Monitoring and follow-up care are crucial for managing treatment responses and side effects.

Cancer was the fifth most common cause of death registered in UAE in 2021, representing 8.2% of all deaths. A total number of 975 invasive cancer deaths were registered for the period 2021. Non-Hodgkin's lymphoma ranked seventh among males and ninth among females. There were 228 cases of non-Hodgkin’s lymphoma accounting for 4.1% of all invasive cancer cases diagnosed in 2021. Non-Hodgkin's lymphoma affected 143 (60%) males and 85 (40%) females. The age-standardized incidence rate (ASR) was 4.9/100,000 for females and 4.5/100,000 for males, and the crude incidence rate was 3/100,000 for females and 2.2/100,000 for males. The market therefore is driven by significant factors like escalating lymphoma incidence rate, increasing healthcare expenditure, and growing geriatric population. However, limited treatment options, a small patient population, adverse effects, and safety concerns restrict the growth and potential of the market.

Prominent players in this field include Bristol Myers Squibb (BMS) and F. Hoffmann-La Roche Ltd. providing diverse lymphoma treatments. Leveraging their expertise, they contribute significantly to meeting the needs of lymphoma patients, and advancing cancer care in the region. Other contributors to the development of treatments for diverse lymphoma include Novartis AG, Kyowa Kirin, and Merck & Co. among others.

Market Dynamics

Market Growth Drivers

Escalating Lymphoma Incidence Rate: Lymphoma's prevalence is on the rise in the UAE, driven by factors like shifting lifestyles, environmental influences, and improved disease detection mechanisms. This surge in cases creates a substantial demand for lymphoma treatments and healthcare services, thereby fuelling market growth.

Increasing Healthcare Expenditure: The UAE's expanding investment in healthcare infrastructure and services is boosting healthcare spending. This uptrend positively impacts the lymphoma market by enhancing access to advanced treatments, diagnostic technologies, and patient care, thereby stimulating market growth.

Growing Geriatric Population: The aging population in the UAE is experiencing a heightened incidence of lymphoma. With age being a significant risk factor for lymphoma, the expanding elderly demographic acts as a catalyst for market expansion, driving the demand for lymphoma treatments and associated healthcare services.

Advancements in T-cell lymphoma Therapies: Continuous research and development endeavors in T-cell lymphoma therapies are leading to the discovery of innovative treatment modalities and targeted therapies. These advancements not only improve treatment efficacy but also introduce new therapeutic options, contributing to market expansion.

Market Restraints

Limited Treatment Options: Despite progress, the array of available lymphoma treatments in the UAE remains limited, especially for certain subtypes and refractory cases. The intricate nature of lymphoma biology and the complexities in developing targeted therapies contribute to this constraint. Consequently, the scarcity of effective treatment options impedes market growth by limiting the ability to adequately address patients' diverse needs.

Small Patient Population: Lymphoma is relatively rare in the UAE, comprising a minor fraction of the overall cancer burden. The limited patient pool poses a challenge for market expansion, as it restricts the potential market size and the commercial viability of lymphoma treatments. Conducting large-scale clinical trials and achieving economies of scale become challenging for pharmaceutical companies, thereby hampering market growth.

Adverse Effects and Safety Concerns: Many existing lymphoma treatments, including chemotherapy and immunotherapy, entail significant side effects and safety concerns. These adverse effects, ranging from mild to severe, can adversely affect patients' quality of life and treatment adherence. Safety apprehensions create a barrier to treatment acceptance and adoption, thus impeding market growth. Overcoming these concerns necessitates the development of safer and more tolerable treatment options tailored to the UAE's patient population.

Regulatory Landscape and Reimbursement Scenario

In the UAE, lymphoma treatment is regulated by several key bodies, including the Ministry of Health and Prevention (MoHAP), Health Authority – Abu Dhabi (HAAD), and Dubai Health Authority (DHA). These regulatory entities oversee the registration and approval of medicines, ensuring their safety and efficacy. Pharmaceutical companies seeking to register lymphoma treatments in the UAE must adhere to a thorough process outlined by MoHAP, which entails submitting comprehensive data on the medication's safety, efficacy, and quality. Upon approval, the medication is included in the UAE's national drug formulary, allowing for its widespread availability and use in healthcare facilities across the country.

Regarding reimbursement for lymphoma treatment in the UAE, the scenario can vary depending on factors such as the type of insurance and the healthcare facility involved. Public insurance programs, like the UAE government's Thiqa health insurance, typically provide substantial coverage for lymphoma treatment expenses for eligible citizens. On the other hand, private insurance plans in the UAE also offer coverage for cancer treatment, albeit with potential out-of-pocket expenses or co-pays depending on the specific plan. Understanding these reimbursement dynamics is crucial for patients and healthcare providers to navigate the financial aspects of lymphoma treatment effectively in the UAE.

Competitive Landscape

Key Players

Here are some of the major key players in the UAE Lymphoma Therapeutic Market:

Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd. (Roche)
Novartis AG
Kyowa Kirin Co., Ltd.
Merck & Co., Inc.
Seattle Genetics, Inc.
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Eisai Co., Ltd.
BeiGene, Ltd.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Lymphoma Therapeutic Market Segmentation

Type of Lymphoma

B-Cell Lymphomas
T-Cell Lymphoma

Treatment Type

Radiation
Chemotherapy
Light Therapy
Surgery
Medication
Others

Diagnosis

Blood Cell Counts
Tissue Biopsy
Computed Tomography (CT) Scan
Positron Emission Tomography (PET) Scan
Magnetic Resonance Imaging (MRI) Scan
Other

End-Users

Hospitals
Homecare
Speciality Centres

Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.